Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Steven D. Weitman"'
Autor:
Clifford J. Whatcott, Chiou Miin Wang, Nameer B. Kirma, Tim H M Huang, Alia Nazarullah, Nicholas D. Lucio, Lars Mouritsen, Chun Liang Chen, Shellye R. Lampkin, Mark Wade, Chih-Wei Chou, Daniel T. DeArmond, Wei-Ting Chao, Ruben A. Mesa, Josephine A. Taverna, Maria Gaczynska, Steven D. Weitman, Meizhen Chen, Chia Nung Hung, David J. Bearss, Steven L. Warner, Lianqun Qiu, Chun-Lin Lin, Pawel A. Osmulski
Publikováno v:
Cancer Res
Cytometry by time-of-flight (CyTOF) simultaneously measures multiple cellular proteins at the single-cell level and is used to assess intertumor and intratumor heterogeneity. This approach may be used to investigate the variability of individual tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed6888ed2ac410d6eca00a87cd018ef6
https://europepmc.org/articles/PMC7127959/
https://europepmc.org/articles/PMC7127959/
Autor:
John G. Kuhn, Zachary N. Warnken, Dan Davis, Hugh D. C. Smyth, Robert O. Williams, Steven D. Weitman
Publikováno v:
Molecular Pharmaceutics. 15:1392-1402
Effective targeting of nasal spray deposition could improve local, systemic, and CNS drug delivery; however, this has proven to be difficult due to the anatomical features of the nasal cavity, including the nasal valve and turbinate structures. Furth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c351ee5f4d1e60f201b73a79156d735
https://doi.org/10.1021/acs.molpharmaceut.7b00702
https://doi.org/10.1021/acs.molpharmaceut.7b00702
Autor:
Ian W. Flinn, Arnold S. Freedman, Kami J. Maddocks, Steven D. Weitman, M. Lia Palomba, Mihaela C. Munteanu, Anastasios Stathis, Emanuele Zucca, Sumit Madan
Publikováno v:
Investigational New Drugs
Summary Background CD37 is expressed on B-cell lymphoid malignancies, thus making it an attractive candidate for targeted therapy in non-Hodgkin lymphoma (NHL). IMGN529 is an antibody-drug conjugate comprising a CD37-binding antibody linked to the ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5a6ab513adcbbdf14e6cfa5cdbe986c
https://doi.org/10.1007/s10637-018-0570-4
https://doi.org/10.1007/s10637-018-0570-4
Autor:
A. Craig Lockhart, Nashat Y. Gabrail, Guru Reddy, Steven D. Weitman, Allen Yang, Anthony J. Olszanski, Steven J. Hasal, Jürgen Venitz, John Sarantopoulos, William Jeffery Edenfield, Kevin R. Kelly
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: Pralatrexate is a folate analogue indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma. It has not been formally tested in patients with renal impairment. This study evaluated the pharmacokinetic (PK) profile of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39285cf286e794d01e7fbf9f88c78b1e
https://doi.org/10.1007/s00280-016-3142-3
https://doi.org/10.1007/s00280-016-3142-3
Autor:
Swaminathan P. Iyer, Karthik Venkatakrishnan, Alexandra Stefanovic, Steven H. Bernstein, Jonathan W. Friedberg, E. Jane Leonard, Xiaofei Zhou, Ari M. Vanderwalde, John Hayslip, Raul R. Mena, Soham D. Puvvada, Gregory Monohan, Daruka Mahadevan, Kevin R. Kelly, Jia Ruan, Anand B. Karnad, Emily Sheldon-Waniga, Monika Schmelz, Peter Rosen, Steven I. Park, Susan Groshen, Daniel O. Persky, Steven D. Weitman, Catherine M. Spier, Kevin T. McDonagh
Publikováno v:
Clin Cancer Res
Purpose: The aurora A kinase inhibitor alisertib demonstrated single-agent clinical activity and preclinical synergy with vincristine/rituximab in B-cell non-Hodgkin lymphoma (B-NHL). This phase I study aimed to determine the safety and recommended p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07b7c08ea73c1a23e1be920e804e80a6
https://europepmc.org/articles/PMC7731903/
https://europepmc.org/articles/PMC7731903/
Autor:
Katherine K. Soh, Peter Peterson, Clifford J. Whatcott, Ye Sol Lee, Hillary Haws, Keith Stewart, Devora Delman, Chang Xin Shi, Steven L. Warner, Adam Siddiqui-Jain, James M Bogenberger, Nanna Hansen, Raoul Tibes, Wontak Kim, Steven D. Weitman, David J. Bearss, Ruben A. Mesa
Publikováno v:
Oncotarget
More effective treatment options for elderly acute myeloid leukemia (AML) patients are needed as only 25-50% of patients respond to standard-of-care therapies, response duration is typically short, and disease progression is inevitable even with some
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87e135cb838c70e8087b3be8a784d39e
https://pubmed.ncbi.nlm.nih.gov/29291023
https://pubmed.ncbi.nlm.nih.gov/29291023
Publikováno v:
European Journal of Cancer. 50:2893-2896
Since the inception of Phase I clinical trials in cancer, patients with renal dysfunc- tion have commonly been excluded from participation because of a poor outlook. Most cancer drugs are approved with limited information on the pharmacokinetics and/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3b79bf4daba177efe1b6de62a4aadbb
https://doi.org/10.1016/j.ejca.2014.09.001
https://doi.org/10.1016/j.ejca.2014.09.001
Autor:
Jessica Hart, Alain C. Mita, John Sarantopoulos, Ahmed Kousba, Kamalesh Kumar Sankhala, Laeeq Malik, Neil Senzer, John Charles, Nicole S. Gallegos, Gavin Anderson, Steven D. Weitman, Devalingam Mahalingam, Jon M. Rogers, John Nemunaitis
Publikováno v:
Cancer Chemotherapy and Pharmacology. 74:1241-1250
ATI-1123 is a liposomal formulation of docetaxel and may be administered without the premedications and hypersensitivity reactions. This Phase I study examines the safety, tolerability, pharmacokinetics (PKs), and antitumor activity of ATI-1123.Patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d21f57e0fd0cf4b118daec858f85623
https://doi.org/10.1007/s00280-014-2602-x
https://doi.org/10.1007/s00280-014-2602-x
Autor:
Q. Yihua, Swami P. Iyer, Philip J. Uren, Luiz O. F. Penalva, Anand B. Karnad, Steven D. Weitman, Sanjay Bansal, Gail E. Tomlinson, Uthra Suresh, Hima Bansal, Suthakar Ganapathy, David A. Proia, Manjeet K. Rao, Steve Kornblau, Jennifer S. Carew
Publikováno v:
Leukemia. 28:1171-1174
The biology of acute myelogenous leukemia (AML) is characterized by a block in differentiation, increase in proliferation and inhibition of apoptosis, all of which when combined lead to an expansion of leukemic blasts.1 AML therapy cures ~20% of thos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2f3ceb9648261e9b85f4056094d1ee7
https://doi.org/10.1038/leu.2014.16
https://doi.org/10.1038/leu.2014.16
Autor:
Steven D. Weitman, Henk-Jan Guchelaar, J.-Y. Blay, Sebastian Bauer, Stefan Sleijfer, R.J.H.M. van der Straaten, M. Ouali, J.M. Kerst, Piotr Rutkowski, Pancras C.W. Hogendoorn, Sandrine Marreaud, Hans Gelderblom, Beatrice Seddon, I.L. Ray-Coquard, Peter Hohenberger, Michael F. Leahy
Publikováno v:
European Journal of Cancer, 50(2), 388-396
European Journal of Cancer, 50(2), 388-396. Elsevier Ltd.
European Journal of Cancer, 50(2), 388-396. Elsevier Ltd.
Aim: Brostallicin is a DNA minor groove binder that has shown activity in patients with soft tissue sarcoma (STS) failing first-line therapy. The present study assessed the safety and efficacy of first-line brostallicin in patients with advanced or m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10871e7402607a54d448d2cbbf9cf346
https://doi.org/10.1016/j.ejca.2013.10.002
https://doi.org/10.1016/j.ejca.2013.10.002